Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
8.720
+0.090 (+1.04%)
Streaming Delayed Price
Updated: 12:09 PM EDT, Apr 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
March 31, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment
March 23, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
March 10, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
March 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
February 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
February 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
↗
February 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 22, 2023
Via
Benzinga
Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.
February 15, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 07, 2023
Via
Benzinga
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
February 09, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer
February 07, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In January: Where Do SPY, Tesla, Apple And Ford Rank?
↗
February 05, 2023
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Via
Benzinga
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
January 13, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
January 06, 2023
Via
Benzinga
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
January 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
December 28, 2022
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
December 22, 2022
Via
Benzinga
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 20, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
December 19, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps
↗
December 14, 2022
U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision.
Via
Benzinga
Dow Surges Over 100 Points; Charter Communications Shares Slide
↗
December 14, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Wednesday
Via
Benzinga
Why Immix Biopharma Shares Are Surging Today?
↗
December 14, 2022
Immix Biopharma Inc (NASDAQ: IMMX) announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101).
Via
Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
↗
December 14, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
December 14, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
December 14, 2022
Via
Benzinga
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)
December 14, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 13, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
December 12, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 02, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
